Discussion
AD, MAPT
In this first in human phase 1b study, bolus IT administrations of four monthly doses of MAPTMAPTLimitations of evaluating CSF t-tau and p-tau to index target engagement include the clearance of existing tau protein and reliance on tau transport to the CSF. Physiological and pathological conditions may impact the rate of synthesis of tau, passive and active release into the extracellular space, and the clearance of tau including degradation by microgliaQuantitative assessment of VV showed greater increases in MAPTMAPTThis first-in-human study of MAPTThese results demonstrate that antisense-mediated suppression of tau protein synthesis in the CNS of participants with mild AD is possible and warrant further evaluation of the effect of MAPT